Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
AGLE

AGLE - Aeglea BioTherapeutics Inc Stock Price, Fair Value and News

27.60USD-0.08 (-0.29%)Market Closed

Market Summary

AGLE
USD27.60-0.08
Market Closed
-0.29%

AGLE Stock Price

View Fullscreen

AGLE RSI Chart

AGLE Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-3.04

Price/Sales (Trailing)

1.3K

EV/EBITDA

-2.42

Price/Free Cashflow

-10

AGLE Price/Sales (Trailing)

AGLE Profitability

EBT Margin

-41104.18%

Return on Equity

-239.2%

Return on Assets

-74.7%

Free Cashflow Yield

-10%

AGLE Fundamentals

AGLE Revenue

Revenue (TTM)

886.0K

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

AGLE Earnings

Earnings (TTM)

-364.2M

Earnings Growth (Yr)

-138.07%

Earnings Growth (Qtr)

30.58%

Breaking Down AGLE Revenue

Last 7 days

14.0%

Last 30 days

51.4%

Last 90 days

158.0%

Trailing 12 Months

122.8%

How does AGLE drawdown profile look like?

AGLE Financial Health

Current Ratio

11.38

AGLE Investor Care

Shares Dilution (1Y)

1440.00%

Diluted EPS (TTM)

-46.08

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
20231.2M1.2M1.1M886.0K
202220.1M7.0M5.8M2.3M
20215.5M9.9M14.3M18.7M
20201.5M1.7M1.1M0
201903.0M1.2M0
20185.7M6.6M5.4M3.9M
20174.8M4.9M5.0M5.2M
20166.9M4.9M5.0M4.6M
20150006.1M

Tracking the Latest Insider Buys and Sells of Aeglea BioTherapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Nov 24, 2023
fairmount funds management llc
acquired
-
-
3,435,480
-
Nov 24, 2023
turtle cameron
acquired
-
-
723,440
chief executive officer
Aug 25, 2022
souza marcio
bought
50,472
0.5608
90,000
-
Jun 08, 2022
hanley jr. michael conick
bought
20,022
0.71
28,200
chief commercial officer
Mar 16, 2022
quinn anthony g.
bought
187,705
2.344
80,079
president & ceo
Mar 15, 2022
quinn anthony g.
bought
78,942
1.8611
42,417
president & ceo
Mar 14, 2022
quinn anthony g.
bought
130,221
1.93
67,472
president & ceo
Mar 11, 2022
quinn anthony g.
bought
71,779
2.064
34,777
president & ceo
Mar 11, 2022
alspaugh jonathan
bought
156,000
2.08
75,000
chief financial officer
Dec 13, 2021
shanafelt armen
bought
53,600
3.65
14,685
-

1–10 of 39

Which funds bought or sold AGLE recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 10, 2024
CITIGROUP INC
added
208
982,952
1,204,540
-%
May 10, 2024
CREDIT SUISSE AG/
new
-
836,585
836,585
-%
May 10, 2024
WELLS FARGO & COMPANY/MN
added
9,647
84,544
85,039
-%
May 10, 2024
OSAIC HOLDINGS, INC.
reduced
-70.67
-2,941
3,147
-%
May 10, 2024
BlackRock Inc.
added
2,716
20,690,000
21,115,300
-%
May 10, 2024
VANGUARD GROUP INC
added
1,160
18,009,200
18,858,100
-%
May 10, 2024
JPMORGAN CHASE & CO
reduced
-73.17
-465
417
-%
May 10, 2024
ACADIAN ASSET MANAGEMENT LLC
sold off
-100
-25,000
-
-%
May 09, 2024
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
new
-
568,950
568,950
-%
May 08, 2024
TD Asset Management Inc
new
-
2,312,520
2,312,520
-%

1–10 of 45

Are Funds Buying or Selling AGLE?

Are funds buying AGLE calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AGLE
No. of Funds

Unveiling Aeglea BioTherapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 25, 2024
fairmount funds management llc
9.99%
4,024,541
SC 13D/A
Apr 23, 2024
avoro capital advisors llc
5.1%
1,839,138
SC 13G/A
Mar 11, 2024
fmr llc
-
0
SC 13G/A
Feb 14, 2024
commodore capital lp
5.4%
1,934,084
SC 13G/A
Feb 14, 2024
deep track capital, lp
6.03%
2,184,440
SC 13G/A
Feb 14, 2024
venrock healthcare capital partners iii, l.p.
9.99%
3,734,514
SC 13G/A
Feb 14, 2024
logos global management lp
0.4%
150,000
SC 13G/A
Feb 14, 2024
avoro capital advisors llc
5.9%
2,125,597
SC 13G
Feb 14, 2024
rock springs capital management lp
0%
0
SC 13G/A
Feb 14, 2024
ecor1 capital, llc
2.5%
887,076
SC 13G/A

Recent SEC filings of Aeglea BioTherapeutics Inc

View All Filings
Date Filed Form Type Document
May 09, 2024
10-Q
Quarterly Report
May 09, 2024
8-K
Current Report
Apr 29, 2024
EFFECT
EFFECT
Apr 25, 2024
4
Insider Trading
Apr 25, 2024
8-K
Current Report
Apr 25, 2024
SC 13D/A
13D - Major Acquisition
Apr 23, 2024
SC 13G/A
Major Ownership Report
Apr 19, 2024
S-1
Initial Public Offering
Apr 02, 2024
ARS
ARS
Apr 02, 2024
SEC STAFF LETTER
SEC STAFF LETTER

Peers (Alternatives to Aeglea BioTherapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
48.2B
6.8B
19.54% -2.80%
-8.07
7.03
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
19.0B
2.0B
0.98% -26.98%
-57.12
9.47
75.20% 68.82%
15.3B
2.5B
-12.72% -14.31%
74.39
6.18
13.74% 186.89%
12.9B
3.8B
6.98% -11.75%
17.35
3.43
8.58% 129.81%
MID-CAP
5.3B
107.9M
6.22% 110.41%
-9.76
48.09
54.84% -28.31%
5.2B
524.1M
-16.95% -51.10%
-12.51
9.96
394.93% 39.61%
3.6B
251.0M
9.36% -4.29%
-12.12
14.31
73.58% -86.73%
2.7B
240.7M
-10.69% -43.90%
-5.82
12.77
-1.03% -213.43%
2.5B
813.8M
-11.38% -29.25%
-1.5K
3.08
56.43% 98.83%
SMALL-CAP
1.9B
411.3M
6.64% 20.67%
29.44
4.66
60.38% -34.49%
1.8B
996.6M
206.31% 55.15%
-4.62
1.85
-26.66% 65.49%
458.7M
881.7K
5.07% 336.18%
-13.59
481.06
-77.61% 33.36%
265.7M
4.9M
3.08% 29.79%
-1.97
54.6
-54.97% 51.71%
6.3M
2.1M
-10.40% 79.21%
-0.23
2.14
-13.45% 66.37%

Aeglea BioTherapeutics Inc News

Latest updates
Yahoo News UK08 May 202407:34 am

Aeglea BioTherapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q32020Q22020Q12019Q32019Q22018Q42018Q32018Q2
Revenue----688,000198,000168,000174,000625,0001,362,0003,644,0001,399,00013,696,0006,892,00088,000161,000300,000585,000619,00012,000-2,378,000
Operating Expenses4.1%47,774,00045,914,00018,337,000159,934,00019,004,00019,330,00018,929,00023,048,00025,803,00024,086,00021,692,00020,401,00018,209,00018,123,00021,560,00019,022,00022,146,00018,622,00015,305,00012,243,00012,048,000
  S&GA Expenses-100.0%-14,072,0008,584,00012,062,0005,228,0005,079,0006,952,0007,675,0008,825,0007,304,0006,839,0006,822,0006,354,0005,672,0004,691,0004,460,0004,307,0003,816,0003,507,0003,314,0002,926,000
  R&D Expenses-----13,776,00014,251,00011,977,00015,373,00016,978,00016,782,00014,853,00013,579,00011,855,00012,451,00016,869,00014,562,00017,839,00014,806,00011,798,0008,929,0009,122,000
EBITDA Margin-7.6%-410-381-278-220-65.61-35.38-14.47-12.21-3.50-3.66-4.62-6.80---------
Income Taxes-32,000-3,0007,000-36,00051,000-209,0009,000-23,00026,00092,000---------
Earnings Before Taxes30.6%-43,825,000-63,180,000-40,104,000-217,074,000-18,458,000-18,771,000-18,443,000-22,314,000-24,436,000-20,423,000-20,281,000-6,738,000--18,033,000-21,418,000------
EBT Margin-7.5%-411-382-279-222-66.94-36.05-14.75-12.44-3.58-3.74-4.73-6.93---------
Net Income30.6%-43,857,000-63,180,000-40,107,000-217,081,000-18,422,000-18,822,000-18,234,000-22,323,000-24,436,000-20,446,000-20,307,000-6,830,000-18,218,000-18,033,000-21,418,000-18,728,000-21,573,000-18,019,000-14,898,000-11,917,000-9,414,000
Net Income Margin-7.5%-411-382-279-221-66.78-35.99-14.72-12.45-3.58-3.51-4.75-6.62---------
Free Cashflow8.0%-28,542,000-31,036,000-34,597,000-16,643,000-17,634,000-18,140,000-15,069,000-20,673,000-26,300,000-19,268,000-17,093,0002,052,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets42.6%48834220724452.0071.0092.0010783.0011012914716416215617365.0083.00100117129
  Current Assets42.7%48734220624044.0062.0082.0097.0073.0099.0011813415115014416254.0075.0093.00110127
    Cash Equivalents20.6%22818991.003.0035.0035.0041.0037.0015.0017.0025.0035.0080.0092.0054.0066.0013.0019.0025.0025.0086.00
  Net PPE-----3.003.004.004.004.005.005.005.006.006.005.005.004.002.001.001.001.00
Liabilities11.8%82.0073.0066.0025419.0021.0024.0023.0022.0026.0027.0028.0040.0022.0019.0021.0022.0023.0020.0018.0012.00
  Current Liabilities33.9%43.0032.0045.0023213.0015.0018.0016.0016.0020.0020.0021.0032.0016.0014.0016.0017.0018.0015.0013.0012.00
Shareholder's Equity-17.3%152184--34.0050.0068.0084.0062.0084.0010211912414013615243.0060.0080.00100116
  Retained Earnings-5.7%-808-764-701-661-444-425-406-388-366-341-321-301-294-276-253-235-213-195-173-152-134
  Additional Paid-In Capital1.7%776763456454478476475473428426423420418416390387257255253252250
Shares Outstanding1.6%37.0036.004.003.003.003.004.003.003.003.003.003.00---------
Float----26.00---30.00---337---386---178-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations8.0%-28,542-31,036-34,597-16,643-17,634-18,140-15,068-20,673-26,263-19,268-17,0002,082-19,530-17,132-17,536-19,413-21,694-16,294-17,208-16,383-15,807
  Share Based Compensation-20.1%13,80017,2704,7851,9111,7091,4271,5662,0172,1012,0942,1072,0801,7571,6121,6961,6001,3481,1841,3661,2451,081
Cashflow From Investing-197.6%-104,963-35,272-97,6316,76017,75014,00016,49975025,7599,6635,777-47,3599,30028,6205,784-56,76114,75310,32616,012-42,01313,936
Cashflow From Financing5.2%172,165163,606-12,531209,99210.00-8.00-13042,80412.0080.001,143-19236224,679258129,293282676311-31965,055
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

AGLE Income Statement

2023-12-31
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenue:   
Total revenue$ 886$ 2,329$ 18,739
Operating expenses:   
Research and development[1]89,50458,57957,069
General and administrative39,94628,53127,319
Acquired in-process research and development130,18800
Gain on sale of in-process research and development asset(16,449)00
Total operating expenses243,18987,11084,388
Loss from operations(242,303)(84,781)(65,649)
Other (expense) income:   
Interest income6,147837111
Other expense, net(19,130)(7)(122)
Total other (expense) income(96,513)830(11)
Loss before income tax expense(338,816)(83,951)(65,660)
Income tax benefit (expense)26136(141)
Net loss$ (338,790)$ (83,815)$ (65,801)
Net loss per share, basic (in dollars per share)$ (49.12)$ (24.86)$ (25.02)
Net loss per share, diluted (in dollars per share)$ (49.12)$ (24.86)$ (25.02)
Weighted-average common shares outstanding, basic (in shares)6,897,0653,371,2312,629,784
Weighted-average common shares outstanding, diluted (in shares)6,897,0653,371,2312,629,784
Forward Contract Liability   
Other (expense) income:   
Change in fair value of forward contract liability$ (83,530)$ 0$ 0
License   
Revenue:   
Total revenue0012,000
Development fee and royalty   
Revenue:   
Total revenue$ 886$ 2,329$ 6,739
[1]Includes $48.5 million in related party expenses for the year ended December 31, 2023 and no related party expenses for the year ended months ended December 31, 2022 and 2021.

AGLE Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
CURRENT ASSETS  
Cash and cash equivalents$ 188,893$ 34,863
Marketable securities150,38420,848
Development receivables0375
Prepaid expenses and other current assets2,2516,172
Total current assets341,52862,258
Restricted cash3221,553
Property and equipment, net03,220
Operating lease right-of-use assets03,430
Other non-current assets9683
TOTAL ASSETS341,85971,144
CURRENT LIABILITIES  
Accounts payable896677
CVR liability1,3900
Operating lease liabilities0625
Deferred revenue0517
Accrued and other current liabilities13,10812,837
Related party accounts payable and other current liabilities16,5840
Total current liabilities31,97814,656
Non-current CVR liability41,3100
Non-current operating lease liabilities04,004
Deferred revenue, net of current portion02,179
TOTAL LIABILITIES73,28820,839
Commitments and Contingencies (Note 9)
Series B non-voting convertible preferred stock, $0.0001 par value; 150,000 and no shares authorized as of December 31, 2023 and December 31, 2022, respectively; 150,000 and no shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively.84,5550
STOCKHOLDERS’ EQUITY  
Common stock, $0.0001 par value; 400,000,000 and 20,000,000 shares authorized as of December 31, 2023 and December 31, 2022, respectively; 36,057,109 shares and 2,614,014 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively.106
Additional paid-in capital763,191475,971
Accumulated other comprehensive income (loss)302(48)
Accumulated deficit(764,414)(425,624)
TOTAL STOCKHOLDERS’ EQUITY184,01650,305
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY341,85971,144
Series A Non-Voting Convertible Preferred Stock  
STOCKHOLDERS’ EQUITY  
Preferred stock184,9270
Preferred Stock  
STOCKHOLDERS’ EQUITY  
Preferred stock$ 0$ 0
AGLE
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
 WEBSITEaeglea.com
 INDUSTRYBiotechnology
 EMPLOYEES14

Aeglea BioTherapeutics Inc Frequently Asked Questions


What is the ticker symbol for Aeglea BioTherapeutics Inc? What does AGLE stand for in stocks?

AGLE is the stock ticker symbol of Aeglea BioTherapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aeglea BioTherapeutics Inc (AGLE)?

As of Tue Apr 30 2024, market cap of Aeglea BioTherapeutics Inc is 1.11 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AGLE stock?

You can check AGLE's fair value in chart for subscribers.

What is the fair value of AGLE stock?

You can check AGLE's fair value in chart for subscribers. The fair value of Aeglea BioTherapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aeglea BioTherapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AGLE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aeglea BioTherapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether AGLE is over valued or under valued. Whether Aeglea BioTherapeutics Inc is cheap or expensive depends on the assumptions which impact Aeglea BioTherapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AGLE.

What is Aeglea BioTherapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 30 2024, AGLE's PE ratio (Price to Earnings) is -3.04 and Price to Sales (PS) ratio is 1.25 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AGLE PE ratio will change depending on the future growth rate expectations of investors.